What Clinicians Need to Know About the Development of Long-Acting Formulations

HIV prevention tool is too slow to reach Africa, activists say

(2022) Andrew Green   SCIENCE

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

(2021) Raphael J. Landovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV

(2019) Jane M. Simoni et al.   AIDS PATIENT CARE AND STDS

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis

(2018) Rahul P. Bakshi et al.   Nature Communications

Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates

(2017) Maria José Fobelo Lozano et al.   European Journal of Hospital Pharmacy-Science and Practice

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy

(2016) Andrew Owen et al.   ADVANCED DRUG DELIVERY REVIEWS

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

(2013) Gabriel Kaplan et al.   Patient Preference and Adherence

Preventing Unintended Pregnancies by Providing No-Cost Contraception

(2012) Jeffrey F. Peipert et al.   OBSTETRICS AND GYNECOLOGY